Benitec Biopharma’s (BNTC) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reissued their market outperform rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report released on Thursday,Benzinga reports. JMP Securities currently has a $20.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of Benitec Biopharma in a research note on Monday, March 24th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $24.71.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $13.50 on Thursday. Benitec Biopharma has a one year low of $5.74 and a one year high of $16.90. The company has a market cap of $316.59 million, a P/E ratio of -8.94 and a beta of 0.34. The firm has a fifty day moving average of $13.67 and a two-hundred day moving average of $12.00.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.12. As a group, equities analysts predict that Benitec Biopharma will post -1.48 earnings per share for the current year.

Insider Buying and Selling

In other Benitec Biopharma news, Director Suvretta Capital Management, L purchased 900,000 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares of the company’s stock, valued at $114,312,185. This trade represents a 11.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. AWM Investment Company Inc. increased its position in Benitec Biopharma by 35.2% during the first quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock worth $1,795,000 after buying an additional 35,950 shares in the last quarter. MYDA Advisors LLC boosted its stake in shares of Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after acquiring an additional 2,000 shares during the last quarter. Informed Momentum Co LLC purchased a new stake in Benitec Biopharma during the 1st quarter worth about $512,000. GAMMA Investing LLC increased its position in Benitec Biopharma by 1,104.3% during the 1st quarter. GAMMA Investing LLC now owns 77,605 shares of the biotechnology company’s stock worth $1,010,000 after purchasing an additional 71,161 shares in the last quarter. Finally, Infinitum Asset Management LLC acquired a new position in Benitec Biopharma in the 4th quarter valued at about $2,652,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.